title: Clinical and pathologic correlates in surgical stage II endometrial carcinoma.
abstract: OBJECTIVE
  To identify the surgical, pathologic, and therapeutic factors that influence outcome in patients with surgical stage II endometrial adenocarcinoma.
  
  
  METHODS
  All patients with comprehensively staged stage II endometrial adenocarcinoma were identified. Data regarding preoperative, surgical, pathologic, adjuvant therapy, and outcomes were collected. Factors were compared with the chi(2) test, and survival curves were generated and compared with the log rank test.
  
  
  RESULTS
  Of 162 patients with surgical stage II endometrial cancer, the median age was 65 years, and the median body mass index was 31.2 kg/m(2). An extrafascial hysterectomy was performed in 75% of cases, whereas 25% of patients underwent radical hysterectomy. At least 10 nodes were recovered in more than 90% of cases. Stage IIA disease was present in 52% of cases, whereas stage IIB accounted for the remaining 48%. After staging, 48% of patients had adjuvant radiation therapy (16% with brachytherapy alone). The remainder received no adjuvant therapy. At a median follow-up of 26 months, 17% experienced disease recurrence. Five-year overall survival rate was 88% and disease-free survival rate was 81%. A significantly better 5-year disease-free survival rate was seen in patients undergoing radical hysterectomy compared with extrafascial hysterectomy (94% compared with 76%, P=.05). Adjuvant radiation did not lead to improved survival.
  
  
  CONCLUSIONS
  In this large series of surgical stage II endometrial cancer cases, improved survival was noted relative to historical controls and in particular with radical compared with extrafascial hysterectomy.
authors.affiliation: Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, Ohio, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Cohn
authors.forename: Emily M
authors.initials: EM
authors.lastname: Woeste
authors.forename: Stacey
authors.initials: S
authors.lastname: Cacchio
authors.forename: Vanna L
authors.initials: VL
authors.lastname: Zanagnolo
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Havrilesky
authors.forename: Andrea
authors.initials: A
authors.lastname: Mariani
authors.forename: Karl C
authors.initials: KC
authors.lastname: Podratz
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
authors.forename: Jenny M
authors.initials: JM
authors.lastname: Whitworth
authors.forename: D Scott
authors.initials: DS
authors.lastname: McMeekin
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Powell
authors.forename: Emily
authors.initials: E
authors.lastname: Boyd
authors.forename: Gary S
authors.initials: GS
authors.lastname: Phillips
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Fowler
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000368:Aged; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008875:Middle Aged; D009215:Myometrium / Q000473:pathology; D016019:Survival Analysis